2022
Practice patterns and real-life outcomes for patients with acute promyelocytic leukemia in the United States
Bewersdorf JP, Prozora S, Podoltsev NA, Shallis R, Huntington SF, Neparidze N, Wang R, Zeidan AM, Davidoff AJ. Practice patterns and real-life outcomes for patients with acute promyelocytic leukemia in the United States. Blood Advances 2022, 6: 376-385. PMID: 34724703, PMCID: PMC8791583, DOI: 10.1182/bloodadvances.2021005642.Peer-Reviewed Original ResearchConceptsAcute promyelocytic leukemiaAdverse outcomesPromyelocytic leukemiaNational Comprehensive Cancer Network guidelinesBaseline white blood cell countFavorable long-term prognosisWhite blood cell countVizient Clinical Data BaseGuideline-concordant regimensGuideline-concordant therapyGuideline-concordant treatmentGuideline-recommended therapiesBaseline clinical characteristicsHigh-risk diseaseLong-term prognosisPopulation-based registryBlood cell countClinical data baseLarge database analysisLogistic regression modelsTreatment concordanceClinical characteristicsReal-world practiceTreatment patternsNetwork guidelines
2021
Disparity in utilization of multiagent therapy for acute promyelocytic leukemia (APL): A large National Cancer Database (NCDB) analysis.
Dhakal P, Lyden E, Gundabolu K, Zeidan A, Loh K, Fisher A, Bhatt V. Disparity in utilization of multiagent therapy for acute promyelocytic leukemia (APL): A large National Cancer Database (NCDB) analysis. Journal Of Clinical Oncology 2021, 39: 6587-6587. DOI: 10.1200/jco.2021.39.15_suppl.6587.Peer-Reviewed Original ResearchSingle-agent therapyAcute promyelocytic leukemiaCommunity cancer centerMultiagent therapyAgent therapyCancer CenterReal-world practiceUninsured patientsClinical trialsComprehensive community cancer centerNational Cancer Database AnalysisMultiple logistic regression analysisFindings highlight disparitiesLower comorbidity indexThird of patientsAcademic cancer centerAppropriateness of treatmentHealth system factorsAcute myeloid leukemiaLogistic regression analysisUnknown therapyComorbidity indexGreater comorbidityMultiagent chemotherapyOverall survival
2014
Real-Life Experience of a Brief Arsenic Trioxide-Based Consolidation Chemotherapy in the Management of Acute Promyelocytic Leukemia: Favorable Outcomes With Limited Anthracycline Exposure and Shorter Consolidation Therapy
Leech M, Morris L, Stewart M, Smith BD, Bashey A, Holland K, Solomon S, Zhang X, Carraway HE, Pratz K, Gore SD, Zeidan AM. Real-Life Experience of a Brief Arsenic Trioxide-Based Consolidation Chemotherapy in the Management of Acute Promyelocytic Leukemia: Favorable Outcomes With Limited Anthracycline Exposure and Shorter Consolidation Therapy. Clinical Lymphoma Myeloma & Leukemia 2014, 15: 292-297. PMID: 25499624, PMCID: PMC4409502, DOI: 10.1016/j.clml.2014.11.001.Peer-Reviewed Original ResearchConceptsAcute promyelocytic leukemiaHigh-risk acute promyelocytic leukemiaConsolidation chemotherapyConsolidation therapyPromyelocytic leukemiaEffective consolidation therapyEvent-free survivalLeukemia-free survivalTrans retinoic acidArsenic trioxide combinationsChemotherapy regimenAnthracycline exposureOverall survivalSecondary malignanciesCardiac toxicityFavorable outcomeRetrospective analysisArsenic trioxideTherapyRetinoic acidChemotherapyPatientsSurvivalLeukemiaMonths
2013
Validation Of a Brief Arsenic Trioxide (ATO)-Based Consolidation Chemotherapy In The Upfront Management Of Acute Promyelocytic Leukemia (APL): Less Anthracycline Exposure and Faster Completion Of Consolidation Therapy With Equivalent Survival
Leech M, Stewart M, Zhang X, Bashey A, Holland H, Solomon S, Carraway H, Smith B, Morris L, Gore S, Zeidan A. Validation Of a Brief Arsenic Trioxide (ATO)-Based Consolidation Chemotherapy In The Upfront Management Of Acute Promyelocytic Leukemia (APL): Less Anthracycline Exposure and Faster Completion Of Consolidation Therapy With Equivalent Survival. Blood 2013, 122: 3963. DOI: 10.1182/blood.v122.21.3963.3963.Peer-Reviewed Original ResearchAcute promyelocytic leukemiaLeukemia-free survivalComplete remissionOverall survivalAnthracycline exposureConsolidation chemotherapyMaintenance therapyIntensive therapyOriginal trialM2/dATRA-ATO combinationContinuous infusion cytarabineSignificant cardiac toxicityLow-risk diseaseMonths of therapyHigh-risk diseaseKaplan-Meier methodologyOriginal clinical trialsCourse of therapyCompletion of protocolTrans retinoic acidChemotherapy consolidationConsolidation therapyInduction therapyIntravenous daunorubicin